Pulike Biological Engineering, Inc. (SHA:603566)

Market Cap	3.61B -28.6%
Revenue (ttm)	1.02B -8.7%
Net Income	146.14M +8.2%
EPS	0.43 +7.8%
Shares Out	341.92M
PE Ratio	24.53
Forward PE	21.10
Dividend	0.60 (5.76%)
Ex-Dividend Date	Jun 16, 2026

Volume	1,396,200
Open	10.53
Previous Close	10.55
Day's Range	10.43 - 10.55
52-Week Range	9.56 - 14.88
Beta	0.30
Analysts	Strong Buy
Price Target	14.75 (+41.01%)
Earnings Date	Aug 25, 2026

About SHA:603566

Pulike Biological Engineering, Inc. engages in the research, development, production, and sale of veterinary biological products, chemical drugs, and traditional Chinese veterinary drugs. The company offers vaccines, antibodies, and medicines for livestock, poultry, and pets. Pulike Biological Engineering, Inc. was founded in 1995 and is headquartered in Luoyang, China.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1995
• Employees: 1,519
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 603566

Financial Performance

In 2025, SHA:603566's revenue was 1.09 billion, an increase of 4.54% compared to the previous year's 1.04 billion. Earnings were 184.99 million, an increase of 99.33%.

Analyst Summary

According to 3 analysts, the average rating for 603566 stock is "Strong Buy." The 12-month stock price target is ¥14.75, which is an increase of 41.01% from the latest price.

Price Target

¥14.75

(41.01% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 2, 2026

Data Sources Report a data error